ES2566960T3 - Tratamiento de la insuficiencia cardíaca en los animales mamíferos no humanos con un antagonista de la aldosterona - Google Patents

Tratamiento de la insuficiencia cardíaca en los animales mamíferos no humanos con un antagonista de la aldosterona Download PDF

Info

Publication number
ES2566960T3
ES2566960T3 ES12180334.0T ES12180334T ES2566960T3 ES 2566960 T3 ES2566960 T3 ES 2566960T3 ES 12180334 T ES12180334 T ES 12180334T ES 2566960 T3 ES2566960 T3 ES 2566960T3
Authority
ES
Spain
Prior art keywords
treatment
heart failure
canrenone
spironolactone
human mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12180334.0T
Other languages
English (en)
Inventor
Patricia Ovaert
Florence Bernay
Jerome Guyonnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceva Sante Animale SA
Original Assignee
Ceva Sante Animale SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale SA filed Critical Ceva Sante Animale SA
Application granted granted Critical
Publication of ES2566960T3 publication Critical patent/ES2566960T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Composición veterinaria para su utilización en el tratamiento de la insuficiencia cardíaca en perros y/o gatos que comprende espironolactona o sus metabolitos elegidos entre canrenona, ácido canrenoico, 15β-OH canrenona, 21- OH canrenona, canrenoato de potasio, 7α-tio-espironolactona, 7α-tiometilespironolactona y 6β-hidroxi-7-a- tiometilespironolactona, en asociación con un antagonista del receptor AT-1 de la angiotensina II, un vasodilatador, un digitálico, un beta bloqueador y/o un antagonista cálcico, y un vehículo farmacéuticamente aceptable, caracterizada por que dicha espironolactona o sus metabolitos se administran a una dosis terapéutica comprendida entre 2 y 5 mg/kg/día, en una sola toma.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
en la que el radical RI es un alquilo o un acilo de C1-C3 y R2 es un hidrógeno o un alquilo de C1-C3. Compuestos que pertenecen a esta familia son por ejemplo la 1-a-acetiltio-15β,16β-metilen-7α-metiltio-3-oxo-17α-pregn-4-en5 21,17-carbolactona; y la 15β,16β-metilen-1a,7α-dimetiltio-3-oxo-17α-pregn-4-en-21,17-carbolactona.
(iii) fórmula general III siguiente:
en la que R es un alquilo inferior, preferentemente un grupo metilo, etilo, propilo, y butilo. Como ejemplos, se pueden citar:
10 -y-lactona del ácido 3β,21-dihidroxi-17α-pregna-5,15-dien-17carboxílico; -lactona del 3-acetato del ácido 3β,21-dihidroxi-17α-pregna-5,15-dien-17-carboxílico; -y-lactona del ácido 3β,21-dihidroxi-17α-pregn-5-en-17-carboxílico; -y-lactona del 3-acetato del ácido 3β,21-dihidroxi-17α-pregn-5-en-17-carboxílico; -y-lactona del ácido 21-hidroxi-3-oxo-17α-pregn-4-en-17-carboxílico;
15 -y-lactona del ácido 21-hidroxi-3-oxo-17α-pregna-4,6-dien-17-carboxílico; -y-lactona del ácido 21-hidroxi-3-oxo-17α-pregna-1,4-dien-17-carboxílico; -y-lactona del ácido 7α-acetiltio-21-hidroxi-3-oxo-17a-pregn-4-en-17-carboxílico; y -y-lactona del ácido 7α-acetiltio-21-hidroxi-3-oxo-17a-pregn-4-en-17-carboxílico.
imagen7
7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
ES12180334.0T 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardíaca en los animales mamíferos no humanos con un antagonista de la aldosterona Active ES2566960T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0704584A FR2917975B1 (fr) 2007-06-26 2007-06-26 Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
FR0704584 2007-06-26
US4841908P 2008-04-28 2008-04-28
US48419P 2008-04-28

Publications (1)

Publication Number Publication Date
ES2566960T3 true ES2566960T3 (es) 2016-04-18

Family

ID=38951459

Family Applications (4)

Application Number Title Priority Date Filing Date
ES12180375.3T Active ES2566923T3 (es) 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardíaca en animales mamíferos no humanos con un antagonista de la aldosterona
ES08774270T Active ES2433383T3 (es) 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardiaca en animales mamíferos no humanos mediante un antagonista de la aldosterona
ES12180487.6T Active ES2566924T3 (es) 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardíaca en animales mamíferos no humanos con un antagonista de la aldosterona
ES12180334.0T Active ES2566960T3 (es) 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardíaca en los animales mamíferos no humanos con un antagonista de la aldosterona

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES12180375.3T Active ES2566923T3 (es) 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardíaca en animales mamíferos no humanos con un antagonista de la aldosterona
ES08774270T Active ES2433383T3 (es) 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardiaca en animales mamíferos no humanos mediante un antagonista de la aldosterona
ES12180487.6T Active ES2566924T3 (es) 2007-06-26 2008-06-25 Tratamiento de la insuficiencia cardíaca en animales mamíferos no humanos con un antagonista de la aldosterona

Country Status (10)

Country Link
US (2) US20100183718A1 (es)
EP (5) EP2564855B1 (es)
JP (1) JP5876219B2 (es)
AU (1) AU2008267227B2 (es)
BR (1) BRPI0813882A2 (es)
CA (1) CA2696961C (es)
ES (4) ES2566923T3 (es)
FR (1) FR2917975B1 (es)
PL (4) PL2564854T3 (es)
WO (1) WO2009000843A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
US20090270356A1 (en) * 2008-04-28 2009-10-29 Ceva Sante Animale Sa Compositions and treatments of heart failure in non-human mammal animals
SI2793866T1 (sl) * 2011-12-21 2016-01-29 Novartis Tiergesundheit Ag Nova kombinacija
EP3167876B1 (en) * 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
FR2991179B1 (fr) * 2012-06-01 2016-11-11 Ceva Sante Animale Compositions veterinaires orales appetentes
DK3021832T3 (da) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
ES2593210T3 (es) 2013-12-04 2016-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
BR112020003235A2 (pt) 2017-08-17 2020-08-18 Ceva Sante Animale composições orais e métodos de preparação das mesmas
WO2024039311A1 (en) * 2022-08-16 2024-02-22 Imuneks Farma Ilac San. Ve Tic. A.S. Treatment of diseases caused by rna viruses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
ES482789A0 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
FR2444047A1 (fr) * 1978-12-13 1980-07-11 Roussel Uclaf Nouveaux derives 2,2-dimethyl 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
FR2569408B1 (fr) * 1984-08-24 1986-10-03 Roussel Uclaf Nouveaux steroides substitues en position 10 par un radical comportant une double ou triple liaison, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
FR2594829B1 (fr) * 1986-02-24 1988-06-03 Roussel Uclaf Nouveaux steroides 9 (11) satures substitues en position 10 par un radical comportant une triple liaison, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
DE69628821T2 (de) 1995-02-10 2004-05-06 G.D. Searle & Co., Skokie Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie
EP1280533A2 (en) * 2000-05-11 2003-02-05 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
ATE363917T1 (de) * 2001-07-19 2007-06-15 Pharmacia Corp Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
WO2003070278A1 (en) * 2002-02-19 2003-08-28 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
JP2004016070A (ja) * 2002-06-14 2004-01-22 Hitachi Ltd オーソログ遺伝子発現分布測定用オリゴヌクレオチドアレイ
CA2495376A1 (en) * 2002-08-23 2004-03-04 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
JP4783887B2 (ja) * 2005-02-17 2011-09-28 国立大学法人大阪大学 心筋組織の障害を抑制するための医薬組成物
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
US20090270356A1 (en) * 2008-04-28 2009-10-29 Ceva Sante Animale Sa Compositions and treatments of heart failure in non-human mammal animals

Also Published As

Publication number Publication date
FR2917975A1 (fr) 2009-01-02
EP2564856A1 (fr) 2013-03-06
EP2170349A2 (fr) 2010-04-07
US20200016155A1 (en) 2020-01-16
WO2009000843A3 (fr) 2009-07-23
ES2566924T3 (es) 2016-04-18
WO2009000843A2 (fr) 2008-12-31
EP2564855A1 (fr) 2013-03-06
CA2696961A1 (fr) 2008-12-31
JP2010531333A (ja) 2010-09-24
CA2696961C (fr) 2018-07-31
EP2567701A3 (fr) 2013-07-03
PL2564855T3 (pl) 2016-07-29
EP2567701A2 (fr) 2013-03-13
ES2433383T3 (es) 2013-12-10
JP5876219B2 (ja) 2016-03-02
BRPI0813882A2 (pt) 2015-01-13
EP2564855B1 (fr) 2016-01-20
AU2008267227A8 (en) 2010-02-18
AU2008267227A1 (en) 2008-12-31
EP2564854B1 (fr) 2016-01-20
PL2564856T3 (pl) 2016-07-29
PL2170349T3 (pl) 2014-01-31
EP2170349B1 (fr) 2013-08-07
US20100183718A1 (en) 2010-07-22
EP2564856B1 (fr) 2016-01-20
AU2008267227B2 (en) 2014-05-01
ES2566923T3 (es) 2016-04-18
EP2564854A1 (fr) 2013-03-06
PL2564854T3 (pl) 2016-07-29
FR2917975B1 (fr) 2009-10-16

Similar Documents

Publication Publication Date Title
DOP2025000260A (es) Antagonistas del receptor de polipéptido insulinotrópico dependiente de glucosa y usos de estos
SV2010003582A (es) Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales
Eshleman et al. Substituted methcathinones differ in transporter and receptor interactions
PE20120578A1 (es) Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
SV2009003305A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1
AR076936A1 (es) Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
GT201000153A (es) Agonistas novedosos de los receptores de glucocorticoides
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
PE20210924A1 (es) Composiciones para animales, y sus usos
EP3823628A4 (en) <SMALLCAPS/>? ? ?S? ? ? ? ?CERTAIN (2)- <NS1:I>N</NS1:I>?-[(1 <NS2:I>S</NS2:I>?)-1-CYANO-2-PHENYLETHYL]-1,4 -OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
AR076765A1 (es) Compuestos antivirales
BR112014000774A8 (pt) Compostos imidazóis substituídos por 2-piridila como inibidores de alk5 e/ou alk4, composição farmacêutica compreendendo-os e uso terapêutico dos mesmos
CR20170070A (es) Composición, método y preparación del ácido biliar sintético
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
CO6321245A2 (es) Mimeticos de glucocorticoides metodos para su fabricacion cpomposiciones farmaceuticas y uso de los mismos
UY31622A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
CO6400144A2 (es) Derivados aminoéster de alcaloides y composición medicinal de los mismos
PE20091241A1 (es) Derivados de n-bencil, n'-arilcarbonilpiperazina como moduladores del receptor lxr
MX2009003916A (es) Compuestos heterociclicos utiles como agentes anabolicos para animales de ganado.
ECSP099573A (es) Derivados heterocíclicos como receptores muscarínicos m3
PL2512494T3 (pl) Kompozycja materiału nasiennego świń do sztucznej inseminacji loch
AR065864A1 (es) Compuesto de oxi-ciclohexil-piperidinil-dihidro-benzimidazol-2-ona composicion farmacetica que lo comprende su uso para la preparacion de un medicamento y compuestos intermediarios para su preparacion
CO2024016692A2 (es) Derivado de anillo de benceno sustituido con imidazopiridazina, método de preparación, composición farmacéutica y uso
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica